结直肠癌(CRC)是最常见的癌症之一,也是发达国家癌症死亡的第二大原因。早期CRC可能没有症状,症状通常出现在更晚期的疾病中。定期筛查可以识别CRC风险增加的人,以便提供早期治疗。一个经济有效的非侵入性平台,用于筛查和监测CRC患者,可以早期发现和适当治疗疾病,术后需及时应用辅助治疗。在这项研究中,我们在2017年至2019年招募了71例血浆样本队列,其中包括48例经结肠镜和组织病理学证实的TNMI至IV期CRC患者.使用NanoStringnCounter在CRC患者中进行血浆mRNA谱分析。使用Mann-WhitneyU检验分析标准化数据以确定来自CRC患者和健康受试者的样品之间的统计学显著差异。使用Kruskal-WallisH检验对多个组之间的统计学显着差异进行临床表型的多组比较。在选择的27个循环mRNA标记中,在两个或两个以上CRC分期患者的血浆中发现所有这些都过表达(基因表达倍数变化>2).总之,开发了基于NanoString的靶向血浆CRC相关mRNA,该标志物组可以显着区分CRC患者与健康人群,用于使用外周血样品进行CRC的非侵入性诊断。
Colorectal cancer (CRC) is one of the most prevalent cancers and the second leading cause of cancer deaths in developed countries. Early CRC may have no symptoms and symptoms usually appear with more advanced diseases. Regular screening can identify people who are at increased risk of CRC in order to offer earlier treatment. A cost-effective non-invasive platform for the screening and monitoring of CRC patients allows early detection and appropriate treatment of the disease, and the timely application of adjuvant therapy after surgical operation is needed. In this study, a cohort of 71 plasma samples that include 48 colonoscopy- and histopathology-confirmed CRC patients with TNM stages I to IV were recruited between 2017 and 2019. Plasma mRNA profiling was performed in CRC patients using NanoString
nCounter. Normalized data were analyzed using a Mann-Whitney U test to determine statistically significant differences between samples from CRC patients and healthy subjects. A multiple-group comparison of clinical phenotypes was performed using the Kruskal-Wallis H test for statistically significant differences between multiple groups. Among the 27 selected circulating mRNA markers, all of them were found to be overexpressed (gene expression fold change > 2) in the plasma of patients from two or more CRC stages. In conclusion, NanoString-based targeted plasma CRC-associated mRNAs circulating the marker panel that can significantly distinguish CRC patients from a healthy population were developed for the non-invasive diagnosis of CRC using peripheral blood samples.